Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:11:44.709Z.
Calculation as of: 2026-10-06T14:11:44.709Z.
Quote observation: 2026-10-06T14:10:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a
PEG RATIO
N/A
Eledon Pharmaceuticals, Inc.
Market Cap
$192.58M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $192.58M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $191.07M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $202.05M | N/A |
| Journey Medical Corporation (DERM)vs › | $181.64M | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.92M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.68M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $176.13M | N/A |
| Alector, Inc. (ALEC)vs › | $208.17M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $172.62M | N/A |
| MediWound Ltd. (MDWD)vs › | $172.45M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
